Dimethyl fumarate—which has the same active metabolite* as VUMERITY® (diroximel fumarate)—was studied in two separate 2-year clinical trials in people with relapsing-remitting MS.
In the first trial, 410 people took 240 mg of dimethyl fumarate two times a day and 408 took placebo (“a fake pill”). In the second trial, 359 people took 240 mg of dimethyl fumarate two times a day and 363 took placebo.
*A metabolite is part of the medication that remains after the drug has been processed (or metabolized) in the body.
Delay progression of physical disability
Slow development of brain lesions
See the data
Find out more
Get the details
Relapses, also called flare-ups or exacerbations, can be disruptive. Reducing the risk of relapses should be one of the goals of treatment.
Although no relapsing MS medication completely gets rid of relapses, dimethyl fumarate (which has the same active metabolite as VUMERITY) has been shown to reduce relapses compared with placebo.
27% of people taking dimethyl fumarate had a relapse, compared with 46% taking placebo
29% of people taking dimethyl fumarate had a relapse, compared with 41% taking placebo
Dimethyl fumarate cut the number of relapses by 53% compared with placebo
Dimethyl fumarate cut the number of relapses by 44% compared with placebo
When you have relapsing MS, you know how important it is to stay as active and mobile as you possibly can.
Dimethyl fumarate (which has the same active metabolite as VUMERITY) was shown to delay the progression of physical disability, which is an important goal of treatment.
16% of people taking dimethyl fumarate experienced disability progression, compared with 27% taking placebo.
13% of people taking dimethyl fumarate experienced disability progression, compared with 17% taking placebo.
It cannot be determined if this change was due to dimethyl fumarate.
The link between brain lesions and the progression of MS has not been confirmed. However, lesions can happen without you noticing them, and they may be a sign that the disease is active. Lesions revealed on a magnetic resonance imaging (MRI) scan may help your healthcare provider determine how well your treatment is working. Talking to your healthcare provider about the results of your MRI could help with the management of your relapsing MS.
To understand the impact of dimethyl fumarate (which has the same active metabolite as VUMERITY) on brain lesions, researchers looked at lesions using 3 different MRI techniques to determine the age and stage of the lesions. Based on all 3 measures, people taking dimethyl fumarate had fewer lesions compared with those taking placebo.
In Study 1, the lesions studied showed:
(Average number of Gd+
lesions at 2 years)
Gd+ lesions:Inflamed brain tissue that is attacked and considered “active.” These lesions disappear when inflammation decreases.
fewer Gd+ lesions
for dimethyl fumarate
(Average number of new or newly enlarging T2 lesions over 2 years)
T2 lesions: Scars that indicate the long-term impact of MS on the brain. They can either be new lesions or old lesions that develop again.
fewer T2 lesions for dimethyl fumarate
(Average number of newT1 lesions over 2 years)
T1 lesions:Nerve cells in the brain that can’t be repaired, which can mean a loss of function.
fewer T1 lesionsfor dimethylfumarate